Learning Factors in Substance Abuse

Total Page:16

File Type:pdf, Size:1020Kb

Learning Factors in Substance Abuse Learning Factors in Substance Abuse U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • PublIc Health Service • Alcohol, Drug Abuse, and Mental Health Admimistration Learning Factors in Substance Abuse Editor: Barbara A. Ray, Ph.D. Office of Financing and Coverage Policy National Institute on Drug Abuse NIDA Research Monograph 84 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medicine National Federation of Parents for Philadelphla, Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph. D Rensselaer Polytechnic lnstitute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates. Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Associatlon Columbia University of North America New York, New York Washington, DC GILBERT J. BOTVIN, Ph. D Cornell University Medical College HERBERT KLEBER, M.D. Yale University School of Medecine New York, New York New Haven, Connecticut JOSEPH V. BRADY, Ph.D. The Johns Hopkins University School of Medicine RICHARD RUSSO Baltimore, Maryland New Jersey State Department of Health Trenton, New Jersey THEODORE J. CICERO, Ph.D. Washington Universlty School of Medicine St Louis, Missouri NIDA Research Monograph Series CHARLES R. SCHUSTER, Ph.D. Director, NIDA THEODORE M. PINKERT, M.D., J.D. Acting Associate Director for Science, NIDA Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857 Learning Factors in Substance Abuse ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on the range of learning factors that influence the acquisi- tion and treatment of drug abuse, held November 3 and 4, 1988, in Bethesda, MD. The meeting was sponsored by the Office of Science and the Division of Clinical Research, National Institute on Drug Abuse. Dr. Barbara A. Ray, editor of the monograph, who was in the Division’s Clinical and Behavioral Pharmacology Branch at the time of the meeting, is now in the Office of Financing and Coverage Policy. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copy- righted material is permitted only as-part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commer- cial product or company. Trade or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein. DHHS publication number (ADM)88-1576 Alcohol, Drug Abuse, and Mental Health Administration Printed 1988 NIDA Research Monographs are indexed in the Index Medicus. They are selectively included in the coverage of American Statistics index, BioSciences Information Service, Chemical Abstracts, Current Contents, Psvchological Abstracts, and Psychopharmacolgy Abstracts. iv Contents Page Preface vii Drug Anticipation and the Treatment of Dependence 1 Shepard Siegel Classically Conditioned Responses in Opioid and Cocaine Dependence: A Role in Relapse? 25 Anna Rose Childress, A. Thomas McLellan, Ronald Ehrman, and Charles P. O’Brien Types of Conditioning Found in Drug-Dependent Humans 44 Charles P. O’Brien, Anna Rose Childress, A. Thomas McLellan, Ronald Ehrman, and Joseph W. Temes The Economic Shaping of Substance Abuse 62 William D. Lerner and James M. Raczynski The Therapeutic Community and Behavioral Science 74 George De Leon Learning and Unlearning Drug Abuse in the Real World: Clinical Treatment and Public Policy 100 Thomas J. Crowley The Relationship of Stimulus Control to the Treatment of Substance Abuse 122 Warren K. Bickel and Thomas H. Kelly v Social Learning Approaches to Alcohol Relapse: Selected Illustrations and Implications . 141 Peter M. Monti, Damaris J. Rohsenow, David B. Abrams, and Jody A. Binkoff Conditioning Phenomena and the Problem of Relapse in Opioid Addicts and Alcoholics. 161 Roger E. Meyer The Use of Second-Order Schedules To Study the Influence of Environmental Stimuli on Drug-Seeking Behavior . 180 Charles W. Schindler, Jonathan L. Katz, and Steven R. Goldberg Human Drug Taking Under Controlled Laboratory Conditions. 196 Marian W. Fischman, Richard W. Foltin, and Joseph V. Brady List of NIDA Research Monographs . 212 vi Preface Learning, as it is used for this monograph, refers generally to changes in behavior due to experience, whether these changes are in lifestyle or in cellular activities. For the successful treating of drug and alcohol abuse, relearning is necessary at the social, individual, and biologic levels. Our current understanding of how learning contributes to drug and alcohol abuse is covered in several of these reports, as we are shown how drug abuse “teaches” the body and the nervous system to react to previously unimportant events in new and sometimes life-threat- ening ways. In systematic and carefully controlled animal studies, Siegel shows us that repeated experience with a drug can establish a tolerance to it that occurs only in the drug-associated environment. This tolerance derives from the animal’s developing a drug-opposite response to repeated exposures to the drug in certain settings. This association between drug and environment, in some instances, means that setting predicts tolerance better than does the amount, frequency, or duration of drug used. The implications of these findings for human drug abuse are serious. When tolerance has not been learned in a new setting, the unsuspecting drug abuser may take an accustomed dose only to overdose and perhaps die. Similarly striking in Schindler et al. is the demonstration of the power of learning factors over monkeys working for drug to the extent that a drug-associated stimulus exerted stronger control of behavior than the drug itself, a finding that has important implications for treatment and prevention techniques. Learned reactions resulting from drug use occur to both internal (moods) and external (people, places, things) cues. Among these vii reactions are: drug abstinence syndrome, drug craving, positive expectations about use, and intoxication reactions. All of these reactions can occur in drug-associated settings by persons detoxified from the drug for perhaps many years. As Childress et al. show, hypnotically induced moods such as anger or joy can trigger drug or alcohol use, indicating how varied and complex are the learned responses due to substance abuse. Appreciating the variety of simultaneous stimulus variables that control the behavior of drug taking, Fischman et al. conduct research in a life-like human living environment. This experimental environment helps to bridge the procedural gap from the animal laboratory to human drug abuse that is controlled simultaneously by many variables, including social access to others. Experiments with marijuana, for instance, confirm the popular notion that it can raise the probability of eating and socializing. O’Brien et al. discuss the clinical relevance of laboratory studies of conditioning in drug abusers and point out that treatment must take into account transitions in what controls drug taking from first, to casual, to chronic use and dependency, and recognize the importance of stimuli remote from the point of drug taking that may start the chain of behaviors leading to use. De Leon describes the therapeutic community approach to treatment as recognizing the need to teach or reteach the drug abuser. As with any treatment program, techniques that work are used whether or not they have been subjected to rigorous scientific testing. The concept of “internalizing” new beliefs and social values, for example, seems clearly to be an attempt to remove control by the external environment filled with drug-associated cues and to return control to the individual. It is worth noting that the gradual step-by-step process of socialization and education that characterizes the therapeutic community is consistent with the basic principle of learning by successive approximation to behavioral targets. Learning occurs not only in the abuser but in those who make their living by selling
Recommended publications
  • San Juan County Adult Drug Court Participant Handbook
    Participant Manual SEVENTH DISTRICT ADULT DRUG COURT MONTICELLO, UTAH Updated January 2018 Subject to Change 1 2 Welcome to the San Juan County Adult Drug Court This Handbook is designed to introduce you to the San Juan County Drug Court program, answer your questions and provide overall information about the Drug Court Program. As a participant, you will be expected to follow the instructions given in Drug Court by the Judge and comply with the treatment plan developed for you by the treatment team. If you are reading this Handbook it means that we are confident that Drug Court will help you to learn how to make successful choices free of the influence of drugs or alcohol. 3 Table of Contents Welcome to the San Juan County Adult Drug Court ...................................................................... 3 Overview ....................................................................................................................................... 6 Drug Court Team ........................................................................................................................... 7 Judge’s Role ........................................................................................................................... 7 San Juan County Attorney’s Role (Prosecutor) ....................................................................... 8 Defense Attorney Role (Your Attorney) ................................................................................... 8 Probation Officer’s Role .........................................................................................................
    [Show full text]
  • The Impact of NMR and MRI
    WELLCOME WITNESSES TO TWENTIETH CENTURY MEDICINE _____________________________________________________________________________ MAKING THE HUMAN BODY TRANSPARENT: THE IMPACT OF NUCLEAR MAGNETIC RESONANCE AND MAGNETIC RESONANCE IMAGING _________________________________________________ RESEARCH IN GENERAL PRACTICE __________________________________ DRUGS IN PSYCHIATRIC PRACTICE ______________________ THE MRC COMMON COLD UNIT ____________________________________ WITNESS SEMINAR TRANSCRIPTS EDITED BY: E M TANSEY D A CHRISTIE L A REYNOLDS Volume Two – September 1998 ©The Trustee of the Wellcome Trust, London, 1998 First published by the Wellcome Trust, 1998 Occasional Publication no. 6, 1998 The Wellcome Trust is a registered charity, no. 210183. ISBN 978 186983 539 1 All volumes are freely available online at www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as : Tansey E M, Christie D A, Reynolds L A. (eds) (1998) Wellcome Witnesses to Twentieth Century Medicine, vol. 2. London: Wellcome Trust. Key Front cover photographs, L to R from the top: Professor Sir Godfrey Hounsfield, speaking (NMR) Professor Robert Steiner, Professor Sir Martin Wood, Professor Sir Rex Richards (NMR) Dr Alan Broadhurst, Dr David Healy (Psy) Dr James Lovelock, Mrs Betty Porterfield (CCU) Professor Alec Jenner (Psy) Professor David Hannay (GPs) Dr Donna Chaproniere (CCU) Professor Merton Sandler (Psy) Professor George Radda (NMR) Mr Keith (Tom) Thompson (CCU) Back cover photographs, L to R, from the top: Professor Hannah Steinberg, Professor
    [Show full text]
  • Narcotics Dangerous Drugs
    If you have issues viewing or accessing this file contact us at NCJRS.gov. Ir I - This microfiche was produced from documents received for inclusion in the NCJRS data base. Since NCJRS cannot exercise control ovcr the physical condition of the documents submitted, the individual frame quality will vary. The resolution chart on this frame may be used to evaluate the document quality. 1.0 1.1 REFERENCE BOOK -- -- 111111.8 \\\\\1.25 111111.4 \\\\\1.6 NARCOTICS AND MICROCOPY RESOLUTION TEST CHART NATIONAL" BUREAU '.F STANDARDS-\963-A DANGEROUS DRUGS Microfilming procedures used to create this fiche comply with i ! the standards set forth in 41CFR 101·11.504 " Compiled by Points of view or opinions stated in this document an I those of the 3uthorlsj and do not represent the official GLENDALE CRIME LABORATORY position or policies of the U.S. Department o,f Justice. 5909 N. Milwaukee River Parkway Glendale, Wisconsin 53209 U.S. DEPARTMENT OF JUSTICE LAW ENFORCEMENT ASSISTANCE ADMINISTRATION" o NATIONAL CRiMINAL JUSTICE REFERENCE SERVICE WASHINGTON, D.C. 20531 ·00 Q a PRICE $'1 12/9/ 75 .,',' J INTRODUCTION This compilation has been taken from many sources primarily for '- use by participants in seminars and workshops on "Narcotics and Dangerous Drugs" conducted by the Glendale Crime Laboratory and for users of the Glendale Crime Laboratory Automated Teaching System programs on "Narcotics and Dangerous Drugs." This com­ pilation is not meant to be all inclusive. Your comments, criticisms and notation of errors would 'De ap­ preciated. Materials for inclusion in future revision would be ap­ preciated.
    [Show full text]
  • Epidemic November 29, 2018 Jim Hall [email protected] 1
    Epidemic November 29, 2018 Phases of a Drug Epidemic Plateau 35 30 25 Expansion 20 15 10 Users & Problems X Users 1000 & Problems X 5 0 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Yr 10 Incubation Incubation Expansion & Problems # of Users Plateau Decline James N. Hall, Senior Epidemiologist Center for Applied Research on Substance Use and Health Disparities Time Nova Southeastern University Components of Substance Use Disorder Epidemiology Contributing Factors of a Drug Epidemic • Host - The User • Agent – The Substances • Environment - Social, Economic, and Geographic Conditions Contributing Factors – Supply Vectors Contributing Factors – Demand Vectors • Production •Attitudes: • Perceived Harmfulness • Patterns of Trafficking • Perceived Wrongfulness • Price • Acceptance by others • Purity • Desired Effects • Profit • Withdrawal – “Dope Sick” • Public Consensus • Availability • Cost • Poisonous Contamination • Rapid Onset of Action • Access Jim Hall [email protected] 1 Epidemic November 29, 2018 Reoccurring Patterns of Opioid Epidemics: 1880 - 2018 Opioids 1990 - 2018 Reoccurring Heroin & Fentanyls Patterns of 1955 - 1970 Rx Opioids Substance Use 1880 - 1900 Disorder Heroin Epidemics Morphine & Heroin 1880 – 2018 # # of users and level of consequences 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2018 The Morphine Molecule DEFINITION OF OPIOID • Binding to and activating “Similar to opium” the opioid μ receptors in the brain and spine Morphine and similar drugs derived from opium • Principal
    [Show full text]
  • VII. MEDICATIONS to AVOID (Do Not Take These Medications)
    ATTACHMENT #1 TO THE DOUGLAS COUNTY DUI/Drug COURT HANDBOOK VII. MEDICATIONS TO AVOID (Do not take these medications) WARNING: THIS LIST IS NOT INTENDED TO BE ALL INCLUSIVE. ALL MEDICATIONS MUST BE CLEARED THROUGH YOUR COUNSELOR PRIOR TO TAKING. Note: Drug Name® = Brand Name A Actiq® (fentanyl) Adipex-P® (phentermine) Adderall® (dextroamphetamine + amphetamine) alcohol (ethanol, ethyl alcohol) or anything containing ethyl alcohol including “Alcohol-Free” beer. Many over-the-counter liquid preparations such as cough syrups, cold medications, mouthwash, body washes or gels, etc. may contain alcohol and may produce a positive EtG (alcohol) urine drug screen. It is YOUR responsibility to read the labels on these preparations, or ask a pharmacist to make sure the products you use do not contain alcohol. alprazolam (Xanax®) ALURATE Ambien® (zolpidem) amphetamine or any product containing amphetamine or any of its derivatives, such as dextroamphetamine (Dexedrine®), benzphetamine (Didrex®), methamphetamine (Desoxyn®, speed, meth, ice, crystal, etc.), DOM, de- or di-methoxyamphetamine and others. AMYTAL NA. A.P.C. W/DEMEROL APPEDRINE ATARAX Ativan® (lorazepam) atropine or any product containing atropine AtroPen® or any other product containing atropine B B.A.C. BANCAP HC barbiturates, including but not limited to butabarbital (Butisol®), butalbital (Fiorinal® and others), mephobarbital (Mebaral®), phenobarbital (Nembutal®, yellow jackets, (Donnatal®), secobarbital (Seconal®, red devils, Xmas trees, rainbows), thiopental (Pentothal®) and any other
    [Show full text]
  • A Mixed Methods Study of Antidepressant Use and Withdrawal
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by ResearchArchive at Victoria University of Wellington Collateral Damage: A Mixed Methods Study to Investigate the Use and Withdrawal of Antidepressants Within a Naturalistic Population By Susan Thrasher A thesis submitted to Victoria University of Wellington in partial fulfilment of the requirements for the degree of Masters of Science Psychology 2010 ii Abstract The use of modern antidepressants has flourished over the past few decades with the modern attribution of affective disorders such as depression to biomedical causation. However, recent re-examination of clinical trials has raised questions regarding antidepressant drug efficacy, and issues around side effects and dependency are prevalent. In spite of this, as many as 10% of us may be taking these medications (Szabo, 2009). This study examines responses to an anonymous online survey about antidepressant use and withdrawal. Participants included 176 current users, 181 currently withdrawing, 108 ex-users, and a control group of 44 participants who had never used antidepressants. Participant groups were compared quantitatively regarding attitude towards antidepressants use and perceived value, effect on well-being and mood, symptoms and side effects, and their perceived changes in themselves on and off the drugs. Participants were also given the opportunity to include spontaneous comments at the end of the survey which were analysed thematically. Key findings include: 1) Antidepressant users
    [Show full text]
  • 2014 NSDUH Field Interviewer Manual September 2013 I Table of Contents Table of Contents (Continued)
    2014 NATIONAL SURVEY ON DRUG USE AND HEALTH Field Interviewer Manual Field Interviewer Computer Manual Contract No. HHSS283201300001C Project No. 0213757 Prepared for: Substance Abuse and Mental Health Services Administration Rockville, Maryland 20857 Prepared by: Research Triangle Institute September 2013 Field Interviewer:__________________________________________ FI ID No:__________________ 2014 NATIONAL SURVEY ON DRUG USE AND HEALTH Field Interviewer Manual Contract No. HHSS283201300001C Project No. 0213757 Prepared for: Substance Abuse and Mental Health Services Administration Rockville, Maryland 20857 Prepared by: Research Triangle Institute September 2013 2014 NATIONAL SURVEY ON DRUG USE AND HEALTH Field Interviewer Manual Contract No. HHSS283201300001C Project No. 0213757 Prepared for: Substance Abuse and Mental Health Services Administration Rockville, Maryland 20857 Prepared by: Research Triangle Institute September 2013 Research Triangle Institute MISSION To improve the human condition by turning knowledge into practice. VISION To be the world’s leading independent research organization, recognized for solving critical social and scientific problems. VALUES Integrity - We perform with the highest ethical standards of individual and group honesty. We communicate openly and realistically with each other and with our clients. Excellence - We strive to deliver results with exceptional quality and value. Innovation - We encourage multidisciplinary collaboration, creativity and independent thinking in everything we do. Respect for the Individual - We treat one another fairly, with dignity and equity. We support each other to develop to our full potential. Respect for RTI - We recognize that the strength of RTI International lies in our commitment, collectively and individually, to RTI’s vision, mission, values, strategies and practices. Our commitment to the Institute is the foundation for all other organizational commitments.
    [Show full text]
  • Organization and Development of a Computerized Drug-Drug Interaction File
    University of Rhode Island DigitalCommons@URI Open Access Master's Theses 1972 Organization and Development of a Computerized Drug-Drug Interaction File Charles Daniel Mahoney University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Mahoney, Charles Daniel, "Organization and Development of a Computerized Drug-Drug Interaction File" (1972). Open Access Master's Theses. Paper 203. https://digitalcommons.uri.edu/theses/203 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. ( ORGANIZATION AND DEVELOPMENT OF A COMPUTERIZED DRUG-DRUG INTERACTION FILE BY CHARLES DANIEL MAHONEY A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE ( REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN PHARMACY UNIVERSITY OF RHODE ISLAND 1972 ( ( MASTEH OF SCIENCE THESIS OF CHAHLES DANIEL MAHONEY Approved: Thesis Committee: ( Chairman fl(C , ~ ---·----''-'- Dean of the Graduate School UNIVERSITY OF HIIODE ISLAND 1972 ( ( TITLE ABSTRACT COMPUTERIZED DHUG-DRUG INTERACTION FILE ( ii ABS'J'.RACT ( The project was designed to organiz e and develop a comput­ erized drug-drug intera ction file. The methodology for the organ­ ization, storage and retrieval of drug-drug interaction information i s discussed. In order to accor.nplish this objective several requirements were met. Th8y are a s folimvs: (1) Seleciion and evaluation of clin­ ically significant drug-drug interactions from the scientific literature, (2) C reation of a computerized data bank for drug-drug interactions, and (3) Design and developme nt of a computerized printout which reports the i nformation in concise s ummaries.
    [Show full text]
  • CNS-Targeting Pharmacological Interventions for the Metabolic Syndrome
    CNS-targeting pharmacological interventions for the metabolic syndrome Kerstin Stemmer, … , Paul T. Pfluger, Matthias H. Tschöp J Clin Invest. 2019;129(10):4058-4071. https://doi.org/10.1172/JCI129195. Review Series The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae. Find the latest version: https://jci.me/129195/pdf REVIEW SERIES: MECHANISMS UNDERLYING THE METABOLIC SYNDROME The Journal of Clinical Investigation Series Editor: Philipp E. Scherer CNS-targeting pharmacological interventions for the metabolic syndrome Kerstin Stemmer,1,2 Timo D. Müller,1,2 Richard D. DiMarchi,3 Paul T. Pfluger,1,2 and Matthias H. Tschöp1,2,4 1Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany. 2German Center for Diabetes Research (DZD), Neuherberg, Germany. 3Department of Chemistry, Indiana University, Bloomington, Indiana, USA. 4Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany. The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer.
    [Show full text]
  • The Amphetamine Years: a Study of the Medical Applications and Extramedical Consumption of Psychostimulant Drugs in the Postwar United States, 1945-1980
    THE AMPHETAMINE YEARS: A STUDY OF THE MEDICAL APPLICATIONS AND EXTRAMEDICAL CONSUMPTION OF PSYCHOSTIMULANT DRUGS IN THE POSTWAR UNITED STATES, 1945-1980 A Dissertation Presented to The Academic Faculty By Nathan William Moon In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy in History and Sociology of Technology and Science Georgia Institute of Technology December 2009 Copyright © Nathan William Moon 2009 THE AMPHETAMINE YEARS: A STUDY OF THE MEDICAL APPLICATIONS AND EXTRAMEDICAL CONSUMPTION OF PSYCHOSTIMULANT DRUGS IN THE POSTWAR UNITED STATES, 1945-1980 Approved by: Dr. Andrea Tone, Advisor Dr. Steven Usselman Social Studies of Medicine and School of History, Technology & Department of History Society McGill University Georgia Institute of Technology Dr. Douglas Flamming Dr. John Krige School of History, Technology & School of History, Technology & Society Society Georgia Institute of Technology Georgia Institute of Technology Dr. Jonathan Metzl Date Approved: November 2, 2009 Women’s Studies Program and Department of Psychiatry University of Michigan For Michele ACKNOWLEDGEMENTS Even if it has but a single author, a dissertation is the product of many people. This one is no exception, and I am extremely grateful to all of the people who made mine a reality. First, I wish to extend my sincere thanks to my advisor Andrea Tone. She has been a model mentor in every way imaginable. Andrea guided me through the scholarship and shepherded this dissertation project with the utmost diligence and care. Although she had many other responsibilities, Andrea never failed to make time for me. She read my chapters and conference paper proposals, attended my talks, and introduced me to leading scholars in our field.
    [Show full text]
  • Historical Trends and Current Patterns of Methamphetamine Use in the U.S
    Historical Trends and Current Patterns of Methamphetamine Use in the U.S. and 3 NDEWS Sentinel Sites Los Atlanta Angeles Texas Cocaine Pharmaceutical Stimulants Methamphetamine Reoccurring Patterns of Stimulant Epidemics Reoccurring Patterns of Stimulant Epidemics 1880 – 2019 Reoccurring Patterns of Stimulant Epidemics:1880 - 2018 1975 - 2018 Cocaine 1880 - 1920 # of users and level of consequences level and # users of 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2018 Reoccurring Patterns of Stimulant Epidemics:1880 - 2018 Pharmaceutical Stimulants 1929 - 1970 1994 - 2018 # of users and level of consequences level and # users of 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2018 Reoccurring Patterns of Stimulant Epidemics:1880 - 2018 Illicit Methamphetamine 1970 - 1995 2008 - 2018 # of users and level of consequences level and # users of 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2018 Reoccurring Patterns of Stimulant Epidemics: 1880 - 2018 Cocaine Pharmaceutical Stimulants Methamphetamine # of users and level of consequences level and # users of Reoccurring Patterns of Stimulant Epidemics:1880 - 2018 1975 - 2018 Cocaine 1880 - 1920 # of users and level of consequences level and # users of 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2018 Reoccurring Patterns of Stimulant Epidemics:1880 - 2018 Pharmaceutical Stimulants 1929 - 1970 1994 - 2018 # of users and level of consequences level and # users of 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2018 Pharmaceutical Amphetamines • 1887 – First produced in Germany • 1919 – Japan makes more powerful version: methamphetamine • 1929-1945 - First US Epidemic generated by pharmaceutical industry and medical profession • 1933 - Smith, Kline and French (SKF) patented amphetamine SKF marketed it as the Benzedrine Inhaler (325 mg of oily amphetamine base).
    [Show full text]
  • National Household Survey on Drug Abuse, 1982 Questionnaire
    National Household Survey on Drug Abuse, 1982 United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse Data Collection Instrument is sponsored by Terms of Use These data are distributed under the following terms of use. By continuing past this page, you signify your agreement to comply with the requirements as stated below: Privacy of Research Subjects Any intentional identification of a research subject (whether an individual or an organization) or unauthorized disclosure of his or her confidential information violates the promise of confidentiality given to the providers of the information. Disclosure of confidential information may also be punishable under federal law. Therefore, users of data agree: To use these datasets solely for research or statistical purposes and not for re- identification of specific research subjects. To make no use of the identity of any research subject discovered inadvertently and to report any such discovery to CBHSQ and SAMHDA (samhda- [email protected]) Citing Data You agree to reference the recommended bibliographic citation in any of your publications that use SAMHDA data. Authors of publications that use SAMHDA data are required to send citations of their published works for inclusion in a database of related publications. Disclaimer You acknowledge that SAMHSA will bear no responsibility for your use of the data or for your interpretations or inferences based upon such uses. Violations If CBHSQ determines that this terms of use agreement has been violated, then possible sanctions could include: Report of the violation to the Research Integrity Officer, Institutional Review Board, or Human Subjects Review Committee of the user's institution.
    [Show full text]